TITLE

'Huge Sellers' Herald Changes in Japan Drug Pricing

AUTHOR(S)
Macarthur, Donald
PUB. DATE
October 2016
SOURCE
Pharmaceutical Executive;Oct2016, Vol. 36 Issue 10, p40
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article discusses the impact of the government's price rules revision on the pharmaceutical industry of Japan with the introduction of mandatory cost-effectiveness standards. The repricing is unlikely to affect many brands but drugs such as Opdivo and Repatha have been reported as future targets. The increase of the prescription drug sales in the country in 2015 driven by factors related to universal health insurance and fee-for-service provider remuneration is also tackled.
ACCESSION #
120515873

 

Related Articles

  • Should Drug Prices Be Negotiated Under Part D Of Medicare? And If So, How? Frank, Richard G.; Newhouse, Joseph P. // Health Affairs;Jan/Feb2008, Vol. 27 Issue 1, p33 

    Medicare's Part D prescription drug benefit has offered affordable coverage to millions of elderly Americans since its January 2006 implementation. A great deal of concern has been expressed about whether drugs are being purchased in a cost-effective manner. Many believe that the government...

  • 64th CPS Annual General Meeting. Toit, Jan du // South African Pharmaceutical Journal;2014, Vol. 81 Issue 5, p34 

    Information about several papers discussed at the 64th Community Pharmacist Sector's (CPS) Annual General Meeting (AGM) held at the Boardwalk Convention Center in Port Elizabeth, South Africa on May 9, 2014 is presented. Topics include Community Pharmacist Sector (CPS) strategic plan, pricing...

  • A model for the ex ante pricing of new drugs. Turner, Roger; Lasserre, Christophe; Beauchet, Pascal // Journal of Medical Marketing;Sep2007, Vol. 7 Issue 4, p333 

    There are several problems associated with the ex ante pricing of new drugs and a key objection is the delay in launching drugs in order to permit cost-effectiveness analysis and set price. The Commitment Processâ„¢ provides a transparent and workable methodology for setting price upfront...

  • Pricing of forthcoming therapies for hepatitis C in Europe: beyond cost-effectiveness? Vooren, Katelijne; Curto, Alessandro; Garattini, Livio // European Journal of Health Economics;May2015, Vol. 16 Issue 4, p341 

    The article offers information on therapies for hepatitis C in Europe. Topics discussed include pressure of worldwide economic crisis on national health care expenditures, debate on new drugs for hepatitis C in Europe that pose a major threat to pharmaceutical expenditure because of their high...

  • Rebranding 101: Best Practices for Credit Unions. Esposito, Barbara // Credit Union Times;9/2/2015, Vol. 26 Issue 32, p12 

    The article talks about points to ponder before getting into a rebranding exercise as per best practices of rebranding as per Austin and Williams are, to understands one's gain from this exercise do a cost benefit analysis and evaluate all options before plunging into this.

  • PharmacoEconomics issue on overcoming 'fourth hurdle' (NICE).  // PharmacoEconomics & Outcomes News;10/4/2008, Issue 563, p2 

    The article announces the publication of an issue of "PharmacoEconomics" that is devoted to helping pharmaceutical companies better understand the requirements behind the British National Institute for Health and Clinical Excellence's (NICE) requirement of demonstrating that a drug is cost...

  • European pricing and reimbursement: prioritizing price over value.  // PharmaWatch: Monthly Review;Mar2007, Vol. 6 Issue 3, p37 

    The article reports on the need for pharmaceutical companies to implement an efficient pricing and reimbursement (P&R) strategy to handle P&R cost controls that are being employed in the European markets to contain the rising drug costs. The key priorities for companies are to better...

  • Onboard navigation: Successfully steering a PBM relationship. Thomas, Tim // Employee Benefit News;Nov2007, Vol. 21 Issue 14, p11 

    The article looks at specialty pharmacy as an aspect in creating and maintaining a transparent, cost-effective relationship with a primary benefit manager (PBM). It mentions that specialty pharmacy costs may be hidden in medical benefits because they are administered in a physician's office or...

  • These 'savings' might cost you more.  // Consumer Reports Money Adviser;Jul2012, Vol. 9 Issue 7, p4 

    The article presents information on promotions by brand-name drug companies which may not be cost-effective for consumers. Tips are presented on offers for prescription medication which may be misleading, including coupons issued by drug manufacturers, free drug samples of brand-name products,...

  • Economic analysis of a medication assistance program for ambulatory care patients at an urban teaching clinic. Gillespie, Effie L.; Patel, Aarti A.; Henyan, Nickole N.; Sander, Stephen; White, C. Michael; Coleman, Craig I. // Formulary;Jan2006, Vol. 41 Issue 1, p31 

    Objective: Pharmacy-managed medication assistance programs (MAP) have the potential to recoup losses incurred by the pharmacy department, but whether this offsets the personnel cost of the program has not been well-established. The purpose of this study was to conduct a cost-benefit analysis of...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics